Clinical research of transurethral columnar balloon dilation of prostate in the treatment of high-risk benign prostatic hyperplasia

doi:10.3877/cma.j.issn.1674-3253.2021.02.013

Abstract

Abstract:

Objective

To investigate the clinical efficacy of transurethral columnar balloon dilation of prostate for high-risk patients with benign prostatic hyperplasia (BPH).

Methods

The data of 50 high-risk BPH patients admitted to our department From June 2016 to July 2018 were analyzed retrospectively. The patients were divided into the treatment group (23 cases) and the control group (27 cases). Transurethral columnar balloon dilation of prostate was performed in the treatment group, and transurethral plasma kinetic resection of prostate was performed in the control group. The operation time, intraoperative hemoglobin loss, continuous bladder irrigation time, catheter retention time, complication rate and the length of postoperative hospitalization were compared between the two groups. The postoperative quality of life (QOL), the international prostate symptom score (IPSS), maximum urinary flow rate (Qmax) and residual urine volume (RUV) were compared.

Result

All patients were operated successfully. The average operation time in the treatment group was shorter than that of the control group [(16±4) min vs (97±11) min, P=0.001]. The loss of hemoglobin in the treatment group was less than that of the control group [(19±4) g/L vs (75±8) g/L, P=0.017], and the continuous bladder irrigation time was shorter than that of the control group [(1.21±0.14) d vs (3.77±0.52) d, P=0.046]. However, the length of catheter retention and postoperative hospitalization in the treatment group were longer than those in the control group. There was no difference in the post-operative QOL, IPSS, Qmax and RUV during 3 to 12 months follow-up.

Conclusion

Transurethral columnar balloon dilation of prostate is an effective supplement for the treatment of high-risk BPH patients as a result of short operation time, less hemoglobin loss and optimized operation process.

Key words: Benign prostatic hyperplasia, Columnar balloon, Dilation of prostate, High-risk patients

Yifei Zhang, hua Zhang, Shuiping Yin, Chaozhao Liang. Clinical research of transurethral columnar balloon dilation of prostate in the treatment of high-risk benign prostatic hyperplasia[J]. Chinese Journal of Endourology(Electronic Edition), 2021, 15(02): 144-147.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2021.02.013

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2021/V15/I02/144

Figures/Tables 4

References 18

[1]	黄卫国，刘锋，张裕. 柱状水囊扩开术治疗高危高龄良性前列腺增生[J]. 江苏医药, 2012, 28(23): 2868-2869．
[2]	侯淑均，刘红珍，高博, 等. 经尿道柱状水囊前列腺扩开术与经尿道前列腺电切术的对比研究[J]. 中华全科医学, 2017, 15(3): 542-544．
[3]	何兆飞，施东辉，吴红华. 经尿道前列腺等离子电切术治疗大体积高危前列腺增生的临床分析[J]. 国际泌尿系统杂志, 2013, 33(3): 355-358.
[4]	张翼飞，尹水平，梁朝朝. 经尿道前列腺等离子整块剜除术治疗超大体积高危前列腺增生的临床分析[J]. 现代泌尿生殖肿瘤杂志, 2019, 11(5): 301-302.
[5]	王充，刘贤奎，苗晓林, 等. 电切镜测量辅助柱状水囊前列腺扩裂术治疗高龄高危前列腺增生[J]. 中国医科大学学报, 2017, 46(10): 952-954.
[6]	陈禹杰，何云峰，张尧, 等. 经尿道柱状水囊前列腺扩开术治疗中年及高危患者良性前列腺增生[J]. 重庆医学, 2017, 46(32): 4523-4525.
[7]	Mahmood SN, Aghaways I. Safety of ovemight hospitalization after transurethral resection of prostate[J]. Open J Urol, 2016, 6(1): 1-6.
[8]	Kardasevic A, Milicevic S. The correlation between prostate volume in patients with benign prostatic hyperplasiain relation to erectile dysfunction[J]. Med Arch, 2016, 70(6): 449-452．
[9]	Kim HJ, Sun HY, Choi H, et a1. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated Meta-Analysis[,J]. PLoS One, 2017, 12(1): e0169248.
[10]	查金智，吴永平，黄石辰, 等. 局部麻醉下行棒状水囊前列腺扩开术治疗前列腺增生[J]. 中国实用医药, 2018, 13(28): 51-52
[11]	卜威振，曾胜，任力娟, 等. 经尿道柱状水囊前列腺扩开术的研究进展[J]. 临床泌尿外科杂志, 2019, 34(1): 74-76.
[12]	Gandaglia G, Zaffuto E, Fossati NA, et a1. The role of prostatic inflammation in the development and progression of benign and malignant diseases[J]. Curr opinUrol, 2017, 27(2): 99-106.
[13]	王琪，李朝坤，黄亮. 经尿道柱状水囊扩开术治疗高危老年前列腺患者的分析[J]. 中华老年多器官疾病杂志, 2017, 16(6): 423-427.
[14]	孔庆阔，时景伟，刘宾, 等. 经尿道柱状水囊前列腺扩开术治疗老年前列腺增生疗效观察[J]. 中华实验外科杂志, 2018, 35(2): 361-362.
[15]	李仁彪，赵峰，贺彦君, 等. 前列腺突入膀胱内距离对柱状水囊前列腺扩开术疗效的影响[J]. 中国医药与临床, 2017, 17(5): 636-639.
[16]	卜威振，王鑫，王东文, 等. 内镜辅助直视下经尿道柱状水囊前列腺扩开术的疗效分析[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(3): 198-202.
[17]	王充，苗晓林，连文峰, 等. 超声引导下经尿道柱状水囊前列腺扩开术治疗前列腺增生[J]. 微创泌尿外科杂志, 2018, 7(4): 263-266.
[18]	周进. 经尿道柱状水囊前列腺扩开术在良性前列腺增生患者中的应用效果分析[J]. 浙江创伤外科, 2018, 23(5): 930-931.

组别	例数	前列腺大小[(ml，(±s)]	QOL[分，(±s)]	Qmax[ml/s，(±s)]	IPSS[分，(±s)])	RUV[ml，(±s)]	慢性肺部疾病(例)	心功能大于3级(例)	脑血管疾病后遗症(例)	糖尿病(例)	凝血机制异常(例)	膀胱结石(例)	膀胱逼尿肌收缩乏力(例)
治疗组	23	79±27	3.2±1.5	5.0±1.9	26±7	113±6	16	14	6	13	3	4	5
对照组	27	71±33	3.5±0.9	5.7±1.5	25±7	104±6	14	12	3	10	2	3	4
统计值		t=0.78	t=0.72	t=1.36	t=0.89	t=0.68	χ²=1.62	χ²=1.34	χ²=1.89	χ²=1.90	χ²=0.38	χ²=0.41	χ²=0.40
P值		0.83	0.50	0.17	0.33	0.29	0.2	0.25	0.17	0.17	0.51	0.52	0.53

组别	例数	前列腺大小[(ml，(±s)]	QOL[分，(±s)]	Qmax[ml/s，(±s)]	IPSS[分，(±s)])	RUV[ml，(±s)]	慢性肺部疾病(例)	心功能大于3级(例)	脑血管疾病后遗症(例)	糖尿病(例)	凝血机制异常(例)	膀胱结石(例)	膀胱逼尿肌收缩乏力(例)
治疗组	23	79±27	3.2±1.5	5.0±1.9	26±7	113±6	16	14	6	13	3	4	5
对照组	27	71±33	3.5±0.9	5.7±1.5	25±7	104±6	14	12	3	10	2	3	4
统计值		t=0.78	t=0.72	t=1.36	t=0.89	t=0.68	χ²=1.62	χ²=1.34	χ²=1.89	χ²=1.90	χ²=0.38	χ²=0.41	χ²=0.40
P值		0.83	0.50	0.17	0.33	0.29	0.2	0.25	0.17	0.17	0.51	0.52	0.53

组别	例数	手术时间(min)	血红蛋白丢失量(g/l)	导尿管留置时间(d)	术后住院时间(d)	持续膀胱冲洗时间(d)
治疗组	23	16±4	19±4	10.4±0.8	11.2±1.3	1.2±0.1
对照组	27	97±11	75±8	5.7±1.1	5.8±1.3	3.8±0.5
t值		3.52	2.40	2.01	1.69	1.63
P值		<0.001	0.02	0.03	0.04	0.04

组别	例数	手术时间(min)	血红蛋白丢失量(g/l)	导尿管留置时间(d)	术后住院时间(d)	持续膀胱冲洗时间(d)
治疗组	23	16±4	19±4	10.4±0.8	11.2±1.3	1.2±0.1
对照组	27	97±11	75±8	5.7±1.1	5.8±1.3	3.8±0.5
t值		3.52	2.40	2.01	1.69	1.63
P值		<0.001	0.02	0.03	0.04	0.04

组别	例数	死亡	暂时性尿失禁	术后出血	尿道狭窄	并发症发生率(%)
治疗组	23	1	3	0	0	17.4
对照组	27	0	2	1	1	14.8
χ²值		1.15	0.44	0.87	0.87	0.06
P值		0.28	0.51	0.35	0.35	0.80

Please choose a citation manager

Content to export